

Fortis Cancer Summit 2024, Bengaluru

List of Oral Presenters

Date & Time - Saturday 27th January 2024 || 8:00 AM to 9:00 AM (IST)

Sr. no.	Author Name	City	Abstract Title	Hall Name	Institute
1	Dr. Sivaranjani S	Coimbatore	FISHing through a paradigm shift: Impact of ASCO-CAP 2023 update on HER2 low breast cancers redefined by Fluorescent in Situ Hybridisation	Hall C	Kidwai memorial institute of oncology, Bengaluru
2	Dr. Vino Anand S	Chennai	SAFETY PROFILE OF PALBOCICLIB IN GERIATRIC POPULATION (HORMONE POSITIVE,HER2neu NEGATIVE) METASTATIC BREAST CANCER-OUR INSTITUTE EXPERIENCE	Hall C	Madras Medical college, Chennai
3	Ms. Hridya Jayamohan	Kochi	In the pursuit of optimizing treatment outcomes for patients with advanced breast cancer (ABC), This study aimed to assess factors that predict the response to CDK4/6 + ET in patients with ABC. The factors that were evaluated were frequency and pattern of PIK3CA mutations, ER, PR status, Her 2 low status and Ki-67%	Hall C	Amrita Institute of Medical Sciences and Research Centre, Koci, Keralal
4	Dr. Vinodh Kumar. S	Chennai	TREND AND CLINICOPATHOLOGICAL PROFILE OF METASTATIC BREAST CANCER – A RETROSPECTIVE DESCRIPTIVE STUDY FROM A TERTIARY CANCER CENTRE IN INDIA	Hall C	Madras Medical College, Chennai
5	Dr. Abrorjon Yusupbekov	Tashkent	Esophageal cancer and Helicobacter pylori: the role of infection in rehabilitation	Hall C	Tashkent Medical Academy. Tashkent, Uzbekistan
6	Dr. Sudharshan Gupta	Hyderabad	PINEAL PARENCHYMAL TUMOR OF INTERMEDIATE DIFFERENTIATION-A CASE REPORT	Hall C	Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad
7	Dr. Sumanta Das	Delhi	Comparison of IDH mutation, 1p/19q co-deletion, EGFR amplification, MGMT methylation, TERT promoter mutation , p53 immunohistochemistry and Ki67 proliferation index in 200 glioma patients (Astrocytoma, Oligodendroglioma and Glioblastoma) and their prognostic significance	Hall C	Fortis Memorial Research Institute
8	Mr. Zuhaib	Delhi	Effect of alcoholic hepatitis on gut microbiome in India: novel findings	Hall C	Sir Ganga Ram Hospital, Delhi
9	Ms. Rizwana Hasan	Delhi	Four-miRNA panel predicts surgical outcome in advanced colorectal cancer patients: A prospective study	Hall C	Sir Ganga Ram Hospital, Delhi
10	Dr. Varun Jaiswal	Indore	Esophageal cancer ranks ninth in terms of incidence (604,000 new cases) and sixth in mortality (544,076 deaths)	Hall C	SRI AUROBINDO INSTITUTE OF MEDICAL SCIENCES,INDORE
11	Dr. Hemanth S Ghalige	Bhubaneswar	Postoperative complications following Gastric Resection surgeries- Scenario from a Tertiary Care Center in Eastern India	Hall C	AIIMS, Bhubaneswar
12	Dr. Amar Ranjan	Delhi	Chemotherapy induced neuropathy in ovarian cancer	Hall D	IRCH, AIIMS, Delhi
13	Dr. Vinodh Kumar. S	Chennai	Significance of serum beta-HCG in gestational trophoblastic diseases - A retrospective analysis of 10-year data from a tertiary cancer center in India	Hall D	Madras Medical College, Chennai

Fortis Cancer Summit 2024, Bengaluru

List of Oral Presenters

Date & Time - Saturday 27th January 2024 || 8:00 AM to 9:00 AM (IST)

Sr. no.	Author Name	City	Abstract Title	Hall Name	Institute
14	Ms. Sathya Veera Merla	Delhi	SPLENIC B-CELL LYMPHOMA, A NEW CATEGORY IN WHO CLASSIFICATION 2022	Hall D	All India Institute of Medical Sciences, New Delhi
15	Dr. Devang Sarvaiya	Mumbai	LLM Study: A KAP Survey assessing Clinical Perspective in India on Leukemia & Lymphoma Management.	Hall D	Cipla Ltd., Mumbai
16	Dr. V Aditya	Kurnool	Multiple Myeloma: Survival Outcomes of patients treated at a tertiary care Institute in a resource limited setting	Hall D	Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh
17	Dr. Divesh Goyal	Mumbai	ClivCan Study: A Cross Sectional Survey assessing Clinical Perspective in India on liver cancer Management	Hall D	Fortis Escort Hospital, Malviya Nagar, Jaipur
18	Dr. Kesav Ajith	Chennai	AN OUTLIER STORY: LONG SURVIVAL IN EGFR EXON 19 DELETION METASTATIC PANCREATIC ADENOCARCINOMA.	Hall D	APOLLO CANCER CENTER, CHENNAI, TAMIL NADU.
19	Ms. Poonam Yadav	Delhi	Cytokine primed Mesenchymal Stem Cells: A Potent Immunomodulatory Strategy to combat Pancreatic Cancer.	Hall D	Sir Ganga Ram Hospital, New Delhi
20	Dr. Muthulingesh	Bengaluru	Hide and seek of EGFR mutation in metastatic Non-small cell lung cancer! Are we ready to play by doing re-biopsy at first progression? – A Case series.	Hall D	Apollo Hospitals, Bannerghatta road, Bangalore
21	Dr. Swati Shukla	Delhi	Identification and Clinical Significance of Circulating Endothelial Progenitor Cells in Retinoblastoma	Hall D	AIIMS, New Delhi
22	Dr. Ranjeet Kaur	Delhi	Elevated expression of p53, Mdm2, and PTEN in human uveal melanoma	Hall D	All India Institute of Medical Sciences, New Delhi
23	Dr. Vino Anand S	Chennai	PREVALENCE OF ADOLESCENT AND YOUNG ADULT (AYA) CANCERS AND THEIR PSYCHOLOGICAL AND SOCIAL EFFECTS DURING CHEMOTHERAPY -OUR INSTITUTE EXPERIENCE	Hall E	Madras Medical college, Chennai
24	Mr. Saajan	Mumbai	Beyond the Scrubs: Stress, Mental Health and Coping in Oncology Practitioners	Hall E	Fortis Hospital Mulund, Mumbai
25	Dr. Devang Sarvaiya	Mumbai	BTA Study: A KAP Survey assessing Clinical Perspective in India on Role of Bone Targeted Agents in Supportive Care.	Hall E	Cipla Ltd., Mumbai
26	Ms. Tanmaya D	Hyderabad	Importance of Genetic Counseling and Cascade Testing in Cancer Surveillance and Prevention	Hall E	Kamineni Hospitals, LB Nagar, Hyderabad
27	Dr. Divya Mahajan	Chandigarh	Nasopharyngeal Cancer: A Five-Year Retrospective Analysis of Clinical and Epidemiological Characteristics with Survival Insights	Hall E	Government medical college and hospital Chandigarh
28	Dr. Neha Yadav	Ghaziabad	Palliative Chemotherapy with or without Cetuximab for Indian Patients with Larynx and Oropharyngeal Carcinoma: Tertiary care experience from North India	Hall E	Fortis Memorial Research Institute, Gurugram India

Fortis Cancer Summit 2024, Bengaluru

List of Oral Presenters

Date & Time - Saturday 27th January 2024 || 8:00 AM to 9:00 AM (IST)

Sr. no.	Author Name	City	Abstract Title	Hall Name	Institute
29	Dr. Neha Yadav	Ghaziabad	Efficacy and safety of Palliative Chemotherapy with or without Cetuximab in oral cancer: Tertiary care experience from North India	Hall E	Fortis Memorial Research Institute, Gurugram
30	Dr. Akhrorbek Yusupbekov	Tashkent	Risk factors in patients with precancerous diseases of the larynx	Hall E	Tashkent Medical Academy. Tashkent, Uzbekistan
31	Dr. Hemanth S Ghalige	Bhubaneswar	Prognostic implications of Worst pattern of invasion in oral squamous cell carcinoma: Analysis of a prospective database from eastern India	Hall E	AllIMS, Bhubaneswar
32	Dr Pramukh N	Bengaluru	The role of rehab centric MDT in Head and Neck Cancers . A review of current literature and our experience	Hall E	Prashanth Super Speciality hospital
33	Dr. Sudharshan Gupta	Hyderabad	Christie Scheme in Advanced Head and Neck Cancers: Experience from a Tertiary Cancer Centre	Hall E	Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad